Mevion to Open First Pediatric Proton Center in China
A partnership between Mevion Medical Systems and Children’s Hospital of Fudan University in Shanghai and Shanghai Fosun Healthcare (Group) Co., Ltd. will lead to the ﬁrst pediatric proton therapy center in China. As part of the agreement, the three parties will collaborate on the proton therapy center’s development, clinical services, training, and research activities.
The new proton therapy center will be located at StarKids Children’s Hospital Shanghai, on the New Hong Qiao campus of Children’s Hospital of Fudan University. Founded in 1952, the Children’s Hospital of Fudan University is one of the top children’s hospitals in China, leading in clinical services, teaching, and research.
“This joint collaboration represents a signiﬁcant milestone for Mevion and pediatric patients in China. By providing the ﬁrst pediatric hospital in China with direct access to proton therapy, together we embark on a new era of patient care that will provide our life-changing technology to children and their families”, said Tina Yu, chief executive ofﬁcer of Mevion Medical Systems. “We are proud to continue to fulﬁll our mission to provide accessible proton therapy to every corner of the globe.”
According to GLOBALCON 2020, the estimated number of new pediatric cancer patients in China last year was 36,651. However, the lack of operating proton centers and specialized medical professionals has signiﬁcantly limited Chinese pediatric patients’ access to proton therapy.
Call for Papers
ARO is seeking original case reports, research articles, and review articles on innovative topics offering practical applications in radiation oncology. Manuscripts undergo a double-blinded external peer review process, and there is no submission fee.
- First Clinical Results Published for 177Lu-rhPSMA-10.1 in mCRPC Trial
- Opaganib Shown to Protect Against Radiation-Induced Lung Inflammation
- Fusion Licenses Actinium-Based PSMA Targeted Radiotherapy From Heidelberg University and Euratom
- Future of Theranostics in Neurooncology Looks Promising With Recent Advancements
- First Cellular Therapy for Unresectable or Metastatic Melanoma Receives FDA Approval